Press releases
2021
19 March, 2021
First patient dosed in Guard Therapeutics’ phase 1b study of company’s investigational drug ROSgard
Guard Therapeutics today announces that the first patient has been dosed in a phase 1b study of the company’s investigational drug ROSgard. The study is being conducted in patients undergoing open heart surgery who have additional risk factors for acute kidney injury. The phase 1b study is being conducted at Münster University Hospital...
11 February, 2021
Guard Therapeutics patent granted in Australia
Guard Therapeutics has obtained patent protection in Australia for their biological investigational drug ROSgard, both as product and for its use in medicine.